alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 88, Number 248 (Thursday, December 28, 2023)]
[Notices]
[Page 89720]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-28679]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; NIDDK-Special Emphasis 
Panel.
    Date: February 23, 2024.
    Time: 1:00 p.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, NIDDK, Democracy II, Suite 
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Xiaodu Guo, Ph.D., M.D., Scientific Review 
Officer, Review Branch, Division of Extramural Activities, NIDDK, 
National Institutes of Health, Room 7023, 6707 Democracy Boulevard, 
Bethesda, MD 20892-5452, (301) 594-4719, <a href="/cdn-cgi/l/email-protection#6502100a1d25001d1117044b0b0c01010e4b0b0c0d4b020a13"><span class="__cf_email__" data-cfemail="3453415b4c74514c4046551a5a5d50505f1a5a5d5c1a535b42">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: December 22, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-28679 Filed 12-27-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
| Name of Subsidiary                                    |   | Country of Incorporation |
|-------------------------------------------------------|--------|--------------------------|
| SQM Industrial S.A.                                   |   |                     | Chile |
| SQM Nitratos S.A.                                     |   |                     | Chile |
| SQM Salar S.A.                                        |   |                     | Chile |
| Minera Nueva Victoria S.A.                            |   |                     | Chile |
| Servicios Integrales de Transito y Transferencia S.A. |   |                     | Chile |
| Soquimich Comercial S.A.                              |   |                     | Chile |
| SQM North America Corp.                               |   |                     | USA |
| SQM Europe N.V.                                       |   |                     | Belgium |

----
Exhibit 10.14



 





Exhibit 10.14




LANVISION SYSTEMS, INC



Schedule of Directors Compensation


The Company currently pays the Independent Directors’ fees of (i) $1,000 for each regularly
scheduled Board meeting attended, and (ii) $1,000 per day for each special meeting or committee
meeting attended on days when there are no Board meetings. Mr. Patsy is an officer of the Company
and is not separately compensated as a director of the Company.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                          86,359
<SECURITIES>                                         0
<RECEIVABLES>                                2,144,912
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             2,231,271
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               2,896,889
<CURRENT-LIABILITIES>                           30,351
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,000
<OTHER-SE>                                     107,270
<TOTAL-LIABILITY-AND-EQUITY>                 2,896,889
<SALES>                                              0
<TOTAL-REVENUES>                               618,238
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               194,248
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             358,610
<INCOME-PRETAX>                                 65,380
<INCOME-TAX>                                    54,035
<INCOME-CONTINUING>                             54,035
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    54,035
<EPS-PRIMARY>                                    54.04
<EPS-DILUTED>                                    54.04
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                          71,877
<SECURITIES>                                   257,911
<RECEIVABLES>                                  242,205
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               571,993
<PP&E>                                         793,583
<DEPRECIATION>                               (634,867)
<TOTAL-ASSETS>                                 730,710
<CURRENT-LIABILITIES>                           21,398
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,000
<OTHER-SE>                                 (1,980,088)
<TOTAL-LIABILITY-AND-EQUITY>                   730,710
<SALES>                                        236,495
<TOTAL-REVENUES>                               236,495
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,135,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (898,505)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (898,505)
<EPS-PRIMARY>                                  (8.985)
<EPS-DILUTED>                                  (8.985)
        

</TABLE>
```

[Congressional Record Volume 158, Number 121 (Tuesday, September 11, 2012)]
[House]
[Page H5775]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                            9/11 ANNIVERSARY

  (Mr. FRELINGHUYSEN asked and was given permission to address the 
House for 1 minute.)
  Mr. FRELINGHUYSEN. Madam Speaker, I rise today to mark the 11th 
anniversary of the vicious attack on America. I appreciate the 
leadership scheduling a memorial service on the steps of the Capitol 
this morning, but more needs to be said as I fear time and events have 
dulled our memory. It was 11 years ago that our Nation changed forever 
as violent international extremists struck in the streets of Lower 
Manhattan and in the fields of Pennsylvania and at the Pentagon.
  When that day was over and as we learned more about that tragedy and, 
yes, of the murderous attacks and the loss of nearly 3,000 Americans, 
including 700 New Jerseyans, who are from my home State, we witnessed 
neighbors and friends consoling one another, and we watched as 
Americans from all walks of life stood united--side by side--waving the 
Stars and Stripes and lighting candles to honor those lost or missing.
  Today, this afternoon, I must remind our fellow Americans that we are 
still a Nation at war, largely because of those events. We remember 
those who lost their lives on that fateful day, but we also remember 
the sacrifices of those who serve in Iraq and Afghanistan to make sure 
that those responsible for those attacks pay that ultimate sacrifice.

                          ____________________
```
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4753 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
115th CONGRESS
  2d Session
                                H. R. 4753

_______________________________________________________________________

                                 AN ACT

 
   To amend the Federal Reserve Act to require the Vice Chairman for 
Supervision of the Board of Governors of the Federal Reserve System to 
           provide a written report, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Federal Reserve Supervision 
Testimony Clarification Act''.

SEC. 2. VICE CHAIRMAN FOR SUPERVISION REPORT REQUIREMENT.

    Paragraph (12) of section 10 of the Federal Reserve Act (12 U.S.C. 
247b) is amended--
            (1) by redesignating such paragraph as paragraph (11); and
            (2) in such paragraph--
                    (A) by striking ``shall appear'' and inserting 
                ``shall provide written testimony and appear''; and
                    (B) by adding at the end the following: ``If, at 
                the time of any appearance described in this paragraph, 
                the position of Vice Chairman for Supervision is 
                vacant, the Chairman or their designee shall appear 
                instead and provide the required written testimony.''.

            Passed the House of Representatives September 26, 2018.

            Attest:

                                                                 Clerk.
115th CONGRESS

  2d Session

                               H. R. 4753

_______________________________________________________________________

                                 AN ACT

   To amend the Federal Reserve Act to require the Vice Chairman for 
Supervision of the Board of Governors of the Federal Reserve System to 
           provide a written report, and for other purposes.
```
Exhibit 23 


                             ACCOUNTANTS' CONSENT
                             --------------------



The Board of Directors
Buckhead America Corporation:

We consent to  incorporation  by reference in the  Registration  Statement  (No.
333-05313) on Form S-3 and in the Registration  Statement (No. 33-97046) on Form
S-8 of Buckhead  America  Corporation  of our report  dated  February  21, 1997,
except  for note  13,  which is dated  as of  March  13,  1997  relating  to the
consolidated  balance sheets of Buckhead America Corporation and subsidiaries as
of  December  31,  1996 and 1995,  and the related  consolidated  statements  of
income,  shareholders'  equity,  and cash flows for the years then ended,  which
report  appears  in the  December  31,  1996  annual  report  on Form 10- KSB of
Buckhead America Corporation.


                                          KPMG PEAT MARWICK LLP


Atlanta, Georgia
May 29, 1997
# C_2018072EN.01004302.xml

| 26.2.2018 | EN | Official Journal of the European Union | C 72/43 |
| --- | --- | --- | --- |

26.2.2018

EN

Official Journal of the European Union

C 72/43

---

Action brought on 9 January 2018 — Holzer y Cia v EUIPO — Annco (ANN TAYLOR)

(Case T-3/18)

(2018/C 072/55)

Language in which the application was lodged: English

Parties

Parties

Applicant: Holzer y Cia, SA de CV (Mexico City, Mexico) (represented by: N. Fernández Fernández-Pacheco, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (EUIPO)

Defendant:

Other party to the proceedings before the Board of Appeal: Annco, Inc. (New York, New York, United States)

Other party to the proceedings before the Board of Appeal:

Details of the proceedings before EUIPO

Details of the proceedings before EUIPO

Proprietor of the trade mark at issue: Applicant

Proprietor of the trade mark at issue:

Trade mark at issue: EU word mark ‘ANN TAYLOR’ — EU trade mark No 9 865 651

Trade mark at issue:

Procedure before EUIPO: Proceedings for a declaration of invalidity

Procedure before EUIPO

Contested decision: Decision of the Second Board of Appeal of EUIPO of 2 November 2017 in Case R 2370/2016-2

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | admit the action; |
| --- | --- |

—

admit the action;

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | confirm the validity of the registration of the EUTM No 9 865 651 ‘ANN TAYLOR’ for all the products for which the said application sought protection; |
| --- | --- |

—

confirm the validity of the registration of the EUTM No 9 865 651 ‘ANN TAYLOR’ for all the products for which the said application sought protection;

| — | order the intervener to pay the costs of the procedure. |
| --- | --- |

—

order the intervener to pay the costs of the procedure.

Plea in law

Plea in law

| — | The Board of Appeal erred in his analysis regarding: the existence of confusing similarity between the conflicting signs and the knowledge of the proprietor of a confusingly similar trademark when filing its application; the intentions of the proprietor at the time of filing its trademark; the probative value given to the evidences submitted by the cancellation applicant and the burden of proof. |
| --- | --- |

—

The Board of Appeal erred in his analysis regarding: the existence of confusing similarity between the conflicting signs and the knowledge of the proprietor of a confusingly similar trademark when filing its application; the intentions of the proprietor at the time of filing its trademark; the probative value given to the evidences submitted by the cancellation applicant and the burden of proof.

---
```

[Congressional Record Volume 158, Number 127 (Wednesday, September 19, 2012)]
[Extensions of Remarks]
[Page E1561]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                 CONGRATULATING DR. HILLARD M. LAZARUS

                                 ______
                                 

                       HON. STEVEN C. LaTOURETTE

                                of ohio

                    in the house of representatives

                     Wednesday, September 19, 2012

  Mr. LaTOURETTE. Mr. Speaker, I would like to offer my congratulations 
to Dr. Hillard M. Lazarus, in his continued pursuit of excellence in 
care delivery and commitment to medical innovation. During my eighteen 
year tenure in Congress, I have had the great honor of working with the 
University Hospitals Systems (UH) in Cleveland, OH, and experiencing 
firsthand the exceptional commitment to increasing the quality of care 
they provide to patients not just from Northeast Ohio, but from around 
the country. I have also had the opportunity to develop a personal 
relationship with many members of their dedicated team of care 
providers.
  Dr. Hillard Lazarus is one of those extraordinary members of the UH 
team. Dr. Lazarus has over 30 years of distinguished experience in his 
field, and has served as the Director of the Blood and Bone Marrow 
Transplant Program within the Division of Hematology/Oncology at 
Seidman Cancer Center for the past 25 years. In this time, Dr. Lazarus 
has gained a reputation as a leading expert in his field and is widely 
recognized for his contributions in the areas of mesenchymal stem cell 
transplants and autologus stem cell transplantation. As a pioneer in 
non-embryonic stem cells and regenerative medicine, Dr. Lazarus 
performed the first stem cell transplant in the state of Ohio in 1976 
at UH Case Medical Center.
  Dr. Lazarus has been identified as an Outstanding Physician in many 
national and local surveys, was inducted into the Cancer Care Hall of 
Fame and the American Cancer Society, and has received the American 
Cancer Society Lifetime Achievement Research Award. He has also 
authored and co-authored over 270 publications in peer-reviewed 
journals, 46 book chapters and 66 review articles. His record of 
ground-breaking treatments and breakthroughs has helped make Seidman 
Cancer Center a leader in the treatment of leukemia and other blood 
disorders.
  Mr. Speaker, I thank you for the opportunity to share some of the 
highlights of the ongoing work of Dr. Lazarus with the House of 
Representatives. It is so important to recognize innovators like him, 
who pave the way for medical breakthroughs that increase the duration 
and quality of life for millions of Americans. I am proud to offer my 
congratulations and thanks to Dr. Lazarus for his outstanding 
achievements and contributions, as well as his service to Northeast 
Ohio and the United States of America.

                          ____________________
```
### *,11 ii*st * .

IN THE SUPREME COURT OF THE STATE OF MONTANA DA 19-0269 STATE OF MONTANA,

Plaintiffand Appellee, v. KENNETH LEROY WHITLOW,

Defendant and Appellant. ORDER 

# FILED MAR 1 0 2020 Bovven G ree n wood Clerk of Suprerne Court State of Montana This Court granted Appellant a motion for extension of time until December 23, 2019, to file the opening brief in this matter. Nothing further was filed, and the brief became overdue. On January 3,2020,the Court ordered Appellant to file his opening brief within thirty days or the case would be dismissed. Nothing further has been filed. It has also come to the Court's attention that Appellant died on February 14, 2020,rendering the issues in this appeal moot. THEREFORE, IT IS ORDERED that this case is DISMISSED WITH PREJUDICE. The Clerk is directed to provide copies ofthis Order to all counsel ofrecord.

41=, DATED this )

b day ofMarch, 2020.

ChiefJustice 03/10/2020

Case Number: DA 19-0269Justices

2
<PAGE> 1


                                                                   Exhibit 99.4


                  CERTIFICATION OF CHIEF EXECUTIVE OFFICER,
             CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER

    Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
    Section 1350)

      The undersigned, as the Chief Executive Officer, Chief Operating Officer
and Chief Financial Officer of TransCommunity Bankshares Incorporated,
respectively, certify that, to the best of each such individual's knowledge and
belief, the Quarterly Report on Form 10-QSB for the period ended June 30, 2003,
which accompanies this certification fully complies with the requirements of
Section 13(a) of the Securities Exchange Act of 1934 and the information
contained in the periodic report fairly presents, in all material respects, the
financial condition and results of operations of TransCommunity Bankshares
Incorporated at the dates and for the periods indicated. The foregoing
certification is made pursuant to section 906 of the Sarbanes-Oxley Act of
2002 (18 U.S.C. Section 1350) and shall not be relied upon for any other
purpose. The undersigned expressly disclaims any obligation to update the
foregoing certification except as required by law.




                                            /s/  WILLIAM C. WILEY
                                          ------------------------------
                                             William C. Wiley
                                             Chief Executive Officer

                                            /s/  BRUCE B. NOLTE
                                          ------------------------------
                                             Bruce B. Nolte
                                             Chief Operating Officer

                                            /s/  THOMAS M. CROWDER
                                          -------------------------
                                             Thomas M. Crowder
                                             Chief Financial Officer

      Date:  August 11, 2003




A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to TransCommunity Bankshares
Incorporated and will be retained by TransCommunity Bankshares Incorporated and
furnished to the Securities and Exchange Commission or its staff upon request.
# C_2008247EN.01001202.xml

| 27.9.2008 | EN | Official Journal of the European Union | C 247/12 |
| --- | --- | --- | --- |

27.9.2008

EN

Official Journal of the European Union

C 247/12

---

Order of the President of the Court of First Instance of 15 July 2008 — Antwerpse Bouwwerken v Commission

(Case T-195/08 R)

(Application for interim measures - Public procurement - Community tendering procedure - Rejection of tender - Application for suspension of operation and interim measures - Admissibility - Interest in bringing proceedings - Loss of an opportunity - Absence of serious and irreparable damage - No urgency)

(2008/C 247/23)

Language of the case: Dutch

Parties

Applicant: Antwerpse Bouwwerken NV (Antwerp, Belgium) (represented by: J. Verbist and D. de Keuster, lawyers)

Applicant:

Defendant: Commission of the European Communities (represented by: E. Manhaeve, Agent, assisted by M. Gelders)

Defendant:

Re:

Application for interim measures in the context of the tendering procedure launched by the Commission for the construction of a building.

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The costs are reserved. |
| --- | --- |

2.

The costs are reserved.

---
**Exhibit 23.1**

 

 

 

 

 

CONSENT OF INDEPENDENT ACCOUNTANTS

 

 

We hereby consent to the incorporation by reference inthe Registration Statements on Form S-3 (No. 333-81982) and Form S-8 (Nos.33-72656 and 33-74616) of our report dated February 1, 2002 relating to thefinancial statements, which appears in the 2001 Annual Report to Shareholdersof Aetrium Incorporated, which is included in this Annual Report on Form 10-Kfor the year ended December 31, 2001. We also consent to incorporation byreference of our report dated February 1, 2002 relating to the financialstatement schedule, which appears in this Annual Report on Form 10-K.

 

 
| /s/ PricewaterhouseCoopers LLP |
|--------------------------------|
|                           |
| PricewaterhouseCoopers LLP     |
| Minneapolis, Minnesota         |
| March 27, 2002                 |